Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
← catalyst calendarNCT07081633 · readout in 103 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
114actual
Sites
23
Countries
China, Hong Kong
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-05 | actual | When the study began enrolling |
| Primary completion | 2026-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma
Interventions
- Drug: Durvalumab — also filed as MEDI4736
- Drug: Tremelimumab
- Combination product: Lenvatinib
Primary outcome
what the primary-completion date above is the date OFProgression free survival (PFS) per RECIST 1.1
measured From the date of first dose until the date of objective PD per RECIST 1.1 or death, whichever came first. It will be assessed when approximately 69 PFS events have occurred (60% maturity), approximately 8 months after the last patients dosed.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed